Aagaard, K.M., Mastrobattista, J.M., Suter, M.A., Kahr, M., Antony, K.M., Racusin, D.A., Chabarria, K.C., 2016. Marijuana use and its effects in pregnancy. American Journal of Obstetrics and Gynecology 215, 506.e1-506.e7. 

Agar, E., 2015. The role of cannabinoids and leptin in neurological diseases. Acta Neurologica Scandinavica 132, 371–380. 

Akirav, I., Segev, A., Mizrachi Zer-Aviv, T., 2016. Cannabinoids and post-traumatic stress disorder. Behavioural Pharmacology 27, 561–569. 

Almeida, V. de, Martins-de-Souza, D., 2018. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 1–11. 

Andrade, C., 2016. Cannabis and Neuropsychiatry, 1: Benefits and risks. The Journal of Clinical Psychiatry e551–e554. 

Black, E., Hocum, B., Black, K., 2018. Ethics and Science, Cannabinoids and Healthcare. Primary Care Reports 24. 

Boggs, D.L., Nguyen, J.D., Morgenson, D., Taffe, M.A., 2018. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and [Delta]9-Tetrahydrocannabinol. Neuropsychopharmacology 43, 142. 

Bohnert, K.M., Jannausch, M., Ilgen, M.A., Lin, L.A., 2016. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addictive Behaviors 61, 99–103. 

Bonn-Miller, M.O., Carroll, C., S. Thiessen, M., Crosby, K., Gonzalez, R., Walsh, Z., 2017. Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review 51, 15–29. 

Borgelt, L.M., Gedde, M., Anderson, S.L., Rhyne, D.N., 2016. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy n/a-n/a. 

Brodie, M.J., Ben‐Menachem, E., 2018. Cannabinoids for epilepsy: What do we know and where do we go? Epilepsia 59, 291–296. 

Cannabinoids – Cannabidiol; Patent Issued for Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment (USPTO 9844530), 2018. . Journal of Engineering 4327. 

Cawthorne, M.A., Di Marzo, V., Duncan, M., Guy, G.W., Stott, C.G., Stocker, C.J., Hislop, D.C., Silvestri, C., Zaibi, M.S., Wargent, E.T., 2013. The cannabinoid ?9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition & Diabetes 3, e68. 

Clark, A.J., Desroches, J., Boulanger, A., Beaulieu, P., 2016. Medical cannabis: Considerations for the anesthesiologist and pain physician. Canadian Journal of Anesthesia/Journal canadien d’anesthsie 63, 608–624. 

Clauw, D.J., Litinas, E., Boehnke, K.F., 2016. Medical Cannabis use is associated with decreased Opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain. 

Collier, R., 2016. How will pot legalization affect medical marijuana? Canadian Medical Association Journal 188, 792–793. 

Cooper, Z.D., Craft, R.M., 2018. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology 43, 34. 

Curran, H.V., Nutt, D.J., Morgan, C.J., Das, R.K., Bloomfield, M.A., Wall, M.B., Moss, A., Mokrysz, C., Hindocha, C., Harvey, L., et al., 2016. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: An evaluation of the cannabis “amotivational” hypotheses. Psychopharmacology 233, 3537–3552. 

Deiana, S., 2012. Medical use of cannabis. Cannabidiol: A new light for schizophrenia? Drug Testing and Analysis 5, 46–51. 

Dewald, O., 2016. Effekte des Endocannabinoidrezeptors CB2 auf die myokardiale Protektion. Zeitschrift fr Herz-,Thorax- und Gef��chirurgie 30, 415–419. 

Di Marzo, V., De Petrocellis, L., Ligresti, A., 2016. From Phytocannabinoids to Cannabinoid receptors and Endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiological Reviews 96, 1593–1659. 

Di Marzo, V., Pertwee, R.G., Gertsch, J., 2010. Phytocannabinoids beyond the Cannabis plant – do they exist? British Journal of Pharmacology 160, 523–529. 

Ding, X., Xiao, G., Zhang, Y., Pan, Y., Clarke, R.C., Merlin, M.D., Wang, L., Jiang, H., 2016. Ancient Cannabis Burial Shroud in a Central Eurasian Cemetery | SpringerLink. Economic Botany. 

Donvito, Giulia, Sara R. Nass, Jenny L. Wilkerson, and Zachary A. Curry. “The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.” Neuropsychopharmacology 43, no. 1 (January 1, 2018): 52. 

Elvik, R., Rogeberg, O., 2016. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 111, 1348–1359. 

Fakhoury, M., 2016. Role of the Endocannabinoid system in the Pathophysiology of schizophrenia. Molecular Neurobiology. 

Freeman, R.A., Forrest, B.D., Parmar, J.R., 2015. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Research in Social and Administrative Pharmacy. 

Friedman, Daniel, and Joseph I. Sirven. “Historical Perspective on the Medical Use of Cannabis for Epilepsy: Ancient Times to the 1980s.” Epilepsy and Behavior, 2016. 

Fuller, T., 2016. Californians Legalize Marijuana in Vote That Could Echo Nationally – The New York Times. Politics. 

Gaetani, S., Romano, A., De Marco, F., Pace, L., Calcagnini, S., Cassano, T., 2017. Cannabinoid receptor 2 signaling in Neurodegenerative disorders: From pathogenesis to a promising therapeutic target. Frontiers in Neuroscience 11. 

Gallicano, G.I., Santopietro, A., Parsa, K., Khatib, D., Friedrich, J., 2016. The grass isn’t always greener: The effects of cannabis on embryological development. BMC Pharmacology and Toxicology 17. 

George, T.P., Tyndale, R.F., Lerman, C., Hawk, L.W., Cinciripini, P.M., Schnoll, R.A., Ashare, R.L., Rabin, R.A., 2016. Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial. The American Journal on Addictions 25, 291–296. 

Grossman, M., Van Ours, J.C., WIlliams, J., 2016a. Users have a greater awareness of cannabis not being as harmful as abstainers think it is. Health Economics 25. 

Grossman, M., van Ours, J.C., Williams, J., 2016b. Attitudes to legalizing cannabis use. Health Economics n/a-n/a. 

Grotenhermen, Franjo, and Kirsten Müller-Vahl. “Medicinal Uses of Marijuana and Cannabinoids.” Critical Reviews in Plant Sciences 35, no. 5–6 (November 1, 2016): 378. 

Hammond, D., Leatherdale, S.T., Asbridge, M., Shiplo, S., 2016. Medical cannabis use in Canada: Vapourization and modes of delivery. Harm Reduction Journal 13. 

Hand, Andrew, Alexia Blake, Paul Kerrigan, and Phineas Samuel. “History of Medical Cannabis.” Journal of Pain Management 9, no. 4 (October 1, 2016): 387. 

Hashimotodani, Y., Chvez, A., Younts, T., Castillo, P., 2012. Endocannabinoid signaling and Synaptic function. Neuron 76, 70–81. 

Hendricks, P.S., Heitmann, B.L., Larsen, S.C., Andersen, L.B., Mehlsen, J., Rangan, A., Jin, L.Z., 2017. Association between use of Cannabis in adolescence and weight change into Midlife. PLOS ONE 12, e0168897. 

Hill, M.N., Bains, J.S., Patel, S., Morena, M., 2015. Neurobiological interactions between stress and the Endocannabinoid system. Neuropsychopharmacology 41, 80–102. 

Holtzman, S., Capler, R., Kay, R., Belle-Isle, L., Callaway, R., Crosby, K., Walsh, Z., Lucas, P., 2015. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review 35, 326–333. 

Hryhorowicz, S., Walczak, M., Zakerska-Banaszak, O., Słomski, R., 2018. Pharmacogenetics of Cannabinoids. European Journal of Drug Metabolism and Pharmacokinetics 43, 1–12. 

Huestis, M.A., Gaffney, G., Gorelick, D.A., Pierce, R.S., Spurgin, A., Milavetz, G., Brown, T.L., Hartman, R.L., 2016. Cannabis effects on driving longitudinal control with and without alcohol. Journal of Applied Toxicology 36, 1418–1429. 

Huser, W., Fitzcharles, M.-A., 2016. Cannabinoids in the management of Musculoskeletal or rheumatic diseases. Current Rheumatology Reports 18. 

Im, E., Pothoulakis, C., Chung, H.Y., Jo, J., Lee, Y., 2016. Endocannabinoids in the gastrointestinal tract. American Journal of Physiology – Gastrointestinal and Liver Physiology 311, G655–G666. 

Ind, P.W., Ribeiro, L.I., 2016. Effect of cannabis smoking on lung function and respiratory symptoms: A structured literature review. npj Primary Care Respiratory Medicine 26, 16071. 

Iring, A., Hricisák, L., Benyó, Z., 2017. {CB1} receptor-mediated respiratory depression by endocannabinoids. Respiratory Physiology & Neurobiology 240, 48–52. 

Iring, András, László Hricisák, and Zoltán Benyó. “{CB1} Receptor-Mediated Respiratory Depression by Endocannabinoids.” Respiratory Physiology & Neurobiology 240 (2017): 48–52. 

Juhasz, G., E. Csepany, M. Magyar, and A. E. Edes. “Variants in the CNR1 Gene Predispose to Headache with Nausea in the Presence of Life Stress.” Genes, Brain and Behavior 16, no. 3 (March 1, 2017): 384–93. 

Kalant, H., 2016. A critique of cannabis legalization proposals in Canada. International Journal of Drug Policy 34, 5–10. 

Kermode-Scott, B., 2016. Canadians authorised to use cannabis for medical purposes to be allowed to grow their own again. BMJ i4480. 

Khaiser, Minhaz, Meiko Peng, Soha Ahrari, and Mark Pasetka. “Medical Cannabis Dosing Strategies in Pain-Related Conditions: A Scoping Review of Current Literature.” Journal of Pain Management 9, no. 4 (October 1, 2016): 449. 

Kleijnen, J., Westwood, M., Schmidlkofer, S., Ryder, S., Misso, K., Lang, S., Keurentjes, J.C., Hernandez, A.V., Duffy, S., Di Nisio, M., et al., 2015. Cannabinoids for medical use. JAMA 313, 2456. 

Lahat, A., Salomon, N., Yanai, H., 2016. Complementary therapies in inflammatory bowel diseases. Current Gastroenterology Reports 18. 

Laviolette, S.R., Rushlow, W., Renard, J., Zunder, J., Kramar, C., Loureiro, M., Norris, C., 2016. Cannabidiol Modulates fear memory formation through interactions with Serotonergic transmission in the Mesolimbic system. Neuropsychopharmacology 41, 2839–2850. 

Leghissa, A., Hildenbrand, Z.L., Schug, K.A., 2018. A review of methods for the chemical characterization of cannabis natural products. Journal of Separation Science 41, 398–415. 

Maggard, S.R., Stringer, R.J., 2016. Reefer madness to marijuana legalization: Media exposure and American attitudes toward marijuana (1975-2012). Journal of Drug Issues 46, 428–445. 

McCoy, Kathleen L. “Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation.” Mediators of Inflammation 2016 (2016): 1–18. 

Merlin, M.D., Clarke, R.A., 2014. CANNABIS: Ethnobotany and Evolution. University of California Press. 

Merlin, M.D., Clarke, R.C., 2015. Letter to the editor: Small, Ernest. 2015. Evolution and classification of Cannabis sativa (marijuana, Hemp) in relation to human utilization. Botanical review 81(3): 189-294. The Botanical Review 81, 295–305. 

Mller-Vahl, K., Grotenhermen, F., 2012. The Therapeutic Potential of Cannabis and Cannabinoids 109. 

Monte, A.A., Kim, H.S., 2016. Colorado Cannabis legalization and its effect on emergency care. Annals of Emergency Medicine. 

Morgan, V.A., Galletly, C., Castle, D., Watts, G.F., Di Prinzio, P., Waterreus, A., 2016. Metabolic syndrome in people with a psychotic illness: Is cannabis protective? Psychological Medicine 46, 1651–1662. 

Motion, A., Development, Design, W., 2015. Major banks suddenly shunning medical marijuana companies. 

Mounessa, Jessica S., Julia A. Siegel, Cory A. Dunnick, and Robert P. Dellavalle. “The Role of Cannabinoids in Dermatology.” Journal of the American Academy of Dermatology, 2017. 

Nagarkatti, M., Nagarkatti, P.S., Jackson, A.R., Sido, J.M., 2016. Marijuana-derived ?-9-tetrahydrocannabinol suppresses th1/th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. Journal of Molecular Medicine 94, 1039–1051. 

Nagy-Grócz, Gabor, Ferenc Zador, Szabolcs Dvoracskó, and Zsuzsanna Bohar. “Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.” International Journal of Molecular Sciences 18, no. 8 (January 1, 2017): 1617. 

Oei, J.L., 2018. Adult consequences of prenatal drug exposure. Internal Medicine Journal 48, 25–31. 

Okusaga, O.O., Makanjuola, T., Patel, D., Aimienwanu, O.R., Patel, R.A., Goddu, S., Shah, J., Mohite, S., Elkhatib, R., Chotalia, J., et al., 2016. A study of the impact of Cannabis on doses of discharge Antipsychotic medication in individuals with schizophrenia or Schizoaffective disorder. Psychiatric Quarterly. 

Pacher, P., 2006. The Endocannabinoid system as an emerging target of Pharmacotherapy. Pharmacological Reviews 58, 389–462. 

Perdikaris, P., Tsarouchi, M., Fanarioti, E., Natsaridis, E., 2018. Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain. Neuropharmacology 129, 1–15. 

Peretti-Watel, P., Chau, N., Falissard, B., Beck, F., Mayet, A., Khlat, M., Legleye, S., 2016. From cannabis initiation to daily use: Educational inequalities in consumption behaviours over three generations in France. Addiction 111, 1856–1866. 

Pertwee, R.G., 2015. Endocannabinoids. Handbook of Experimental Pharmacology 231. 

Pesce, M., D’Alessandro, A., Borrelli, O., Gigli, S., 2018a. Endocannabinoid‐related compounds in gastrointestinal diseases. Journal of Cellular and Molecular Medicine 22, 706–715. 

Pesce, M., D’Alessandro, A., Borrelli, O., Gigli, S., Seguella, L., Cuomo, R., Esposito, G., Sarnelli, G., 2018b. Endocannabinoid-related compounds in gastrointestinal diseases. J. Cell. Mol. Med. 22, 706–715. 

Piper, Brian J., Rebecca M. DeKeuster, Monica L. Beals, and Catherine M. Cobb. “Substitution of Medical Cannabis for Pharmaceutical Agents for Pain, Anxiety, and Sleep.” Journal of Psychopharmacology 31, no. 5 (May 1, 2017): 569–75. 

Pisanti, Simona, and Maurizio Bifulco. “Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back.” Trends in Pharmacological Sciences, 2016. 

Pistis, M., Fratta, W., Fadda, P., Fattore, L., Melis, M., Muntoni, A.L., Scherma, M., 2016. Interactions between the endocannabinoid and nicotinic cholinergic systems: Preclinical evidence and therapeutic perspectives. Psychopharmacology 233, 1765–1777. 

Porsteinsson, A.P., Makino, K.M., Antonsdottir, I.M., 2016. Dazed and confused: Medical Cannabis in Alzheimer disease. The American Journal of Geriatric Psychiatry. 

Rhyne, Danielle N., Sarah L. Anderson, Margaret Gedde, and Laura M. Borgelt. “Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population.” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36, no. 5 (May 1, 2016): 505–10. 

Rigucci, S., Xin, L., Klauser, P., Baumann, P.S., 2018a. Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. Psychopharmacology 235, 13–22. 

Rigucci, S., Xin, L., Klauser, P., Baumann, P.S., 2018b. Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. Psychopharmacology 235, 13–22. 

Robinson, J.D., Cinciripini, P.M., Karam‐Hage, M., Aubin, H.-J., 2018. Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation. Addiction Biology 23, 291–303. 

Russo, Ethan B. “Beyond Cannabis: Plants and the Endocannabinoid System.” Trends in Pharmacological Sciences, 2016. 

Savage, Seddon R., Alfonso Romero-Sandoval, Michael Schatman, and Mark Wallace. “Cannabis in Pain Treatment: Clinical & Research Considerations.” Journal of Pain, 2016. 

Schlabritz-Loutsevitch, Natalia, Nadjejda German, Gary Ventolini, and Eneko Larumbe. “FETAL SYNDROME OF ENDOCANNABINOID DEFICIENCY (FSECD).” Medical Hypotheses, 2016. 

Sido, Jessica M., Austin R. Jackson, Prakash S. Nagarkatti, and Mitzi Nagarkatti. “Marijuana-Derived Δ-9-Tetrahydrocannabinol Suppresses Th1/Th17 Cell-Mediated Delayed-Type Hypersensitivity through MicroRNA Regulation.” Journal of Molecular Medicine 94, no. 9 (September 1, 2016): 1039–51. 

Siegel, C.A., Brimhall, B., Isfort, R.W., Gerich, M.E., 2014. Medical marijuana for digestive disorders: High time to prescribe? The American Journal of Gastroenterology 110, 208–214. 

Sierra, S., Luquin, N., Navarro-Otano, J., 2018. The endocannabinoid system in cardiovascular function: novel insights and clinical implications. Clinical Autonomic Research 28, 35–52. 

Small, E., 2015. Evolution and classification of Cannabis sativa (marijuana, Hemp) in relation to human utilization. The Botanical Review 81, 189–294. 

Smith, Douglas R., Christine M. Stanley, Theodore Foss, and Richard G. Boles. “Rare Genetic Variants in the Endocannabinoid System Genes CNR1 and DAGLA Are Associated with Neurological Phenotypes in Humans.” PLoS One 12, no. 11 (November 1, 2017): e0187926. 

Stephens, G.J., Whalley, B.J., Williams, C.M., Hill, A.J., 2012. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics 133, 79–97. 

Suliman, N.A., Taib, C.N.M., Moklas, M.A.M., Basir, R., 2018. Delta-9-Tetrahydrocannabinol (∆9-THC) Induce Neurogenesis and Improve Cognitive Performances of Male Sprague Dawley Rats. Neurotoxicity Research 33, 402–411. 

Taub, S., Feingold, D., Rehm, J., Lev-Ran, S., 2018. Patterns of cannabis use and clinical correlates among individuals with Major Depressive Disorder and Bipolar Disorder. Comprehensive Psychiatry 80, 89–96. 

Temple, L.M., 2016. Medical marijuana and pain management. Disease-a-Month 62, 346–352. 

Tennen, H., Armeli, S., O’Hara, R.E., 2016. Alcohol and cannabis use among college students: Substitutes or complements? Addictive Behaviors 58, 1–6. 

Tims, L.A., Birdsall, T.C., Birdsall, S.M., 2016. The use of medical marijuana in cancer. Current Oncology Reports 18. 

Turcotte, Caroline, Marie-Renée Blanchet, Michel Laviolette, and Nicolas Flamand. “The CB2 Receptor and Its Role as a Regulator of Inflammation.” Cellular and Molecular Life Sciences 73, no. 23 (December 1, 2016): 4449–70. 

Udow, S.J., Freitas, M.E., Fox, S.H., Lang, A.E., 2018. Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. CMAJ: Canadian Medical Association Journal 190, E50. 

van Ours, J.C., Palali, A., 2016. Cannabis use and support for cannabis legalization. Empirical Economics. 

Vazirian, M., Nikan, M., Manayi, A., Panahi, Y., 2017. The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomedicine & Pharmacotherapy 86, 620–627. 

Walker, L.A., ElSohly, M.A., Phillips, S., Fasinu, P.S., 2016. Current status and prospects for Cannabidiol preparations as new therapeutic agents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36, 781–796. 

Ware, M., McCarberg, B., Fanciullo, G., Wallace, M., Schatman, M., Romero-Sandoval, A., Savage, S.R., 2016. Cannabis in pain treatment: Clinical and research considerations. The Journal of Pain. 

Wijayendran, S.B., O’Neill, A., Bhattacharyya, S., 2016. The effects of cannabis use on salience attribution: a systematic review. Acta Neuropsychiatrica 1–15. 

Williams, C.M., Whalley, B.J., Duncan, M., Samuels, J., Brierley, D.I., 2016. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology 233, 3603–3613. 

Winstock, A.R., Freeman, T.P., 2015. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine 45, 3181–3189. 

Zhang, X., Chen, W.-W., Huang, W.-J., 2016. Endocannabinoid system: Role in depression, reward and pain control (review). Molecular Medicine Reports.